DDN Webinar October 22nd

Register for the Webinar

Already registered?
Access the webinar here »

Early cancer detection is a key determinant of patient outcomes. Liquid biopsy is a sensitive diagnostic technology that uses peripheral blood to detect biomarkers for solid and liquid tumors. Current technologies detect circulating tumor cells and tumor DNA, but lack the sensitivity to identify cancer biomarkers from proteins present in the circulation. In this webinar, Klaus Pantel and Christoffer Gebhardt will discuss recent advances in liquid biopsy technology that allow researchers to detect protein biomarkers for diverse cancer types, including metastatic melanoma.

Topics to be covered

  • The role of circulating protein biomarkers
  • Technological advances and clinical applications of liquid biopsy
  • Clinical trials for implementing liquid biopsy into clinical routine

Speaker Information:


Klaus Pantel, MD
Chairman and Founding Director, Institute for Tumor Biology
Executive Board Member, University Cancer Center Hamburg (UCCH)
University Medical Center Hamburg-Eppendorf (UKE)
Hamburg, Germany
Visiting Professor, University of Bergen, Norway

Chris circle

Christoffer Gebhardt, MD

Head, University Skin Cancer Center Hamburg

Vice Chairman, Department of Dermatology and Venereology

University Medical Center Hamburg-Eppendorf (UKE)

Hamburg, Germany


Webinar Sponsor